Hair Loss in Women is More Than a Cosmetic Concern
Less than half of women experiencing hair loss have genetic origins as the cause; possible causes and treatments are reviewed.
Less than half of women experiencing hair loss have genetic origins as the cause; possible causes and treatments are reviewed.
The FDA’s Fast Track process allows for expedited review of drugs that are expected to fill an unmet need.
The prevalence and predictors of patient-reported worsening of AD symptoms during pregnancy are examined.
A novel study reports the positive response to oral and topical antifungals for patients with atopic dermatitis (AD) treated with dupilumab who developed facial redness.
A possible link between childhood and adolescence atopic dermatitis and mental health issues in children is investigated.
The Food and Drug Administration has approved Opzelura (ruxolitinib) cream for the short-term and noncontinuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. The approval was based on data…
The risk of bacterial and opportunistic infection in patients with AD treated with systemic immunomodulatory agents is assessed.
Lebrikizumab is a novel humanized monoclonal antibody that selectively inhibits IL-13.
A link between pre- and postnatal exposure to antibiotics and the risk for atopic dermatitis is investigated.
Clinician competence in treating patients of various racial and ethnic backgrounds and the critical need for greater inclusion of diverse populations in trials investigating the pathophysiology and treatment of AD are underscored.